(Reuters) - Eighteen French biotech firms, several newly listed on the Paris stock market, head to New York on Wednesday and Thursday to convince U.S. investors to help fund the next stages of their research and development.
Among them are companies specialized in therapeutic vaccines (Genticel), cell-based immunotherapy (TxCell), genetic disease diagnostics (Genomic Vision) and needle-free injections (Crossject).
Help employers find you! Check out all the jobs and post your resume.
